The sodium-glucose cotransporter 2 (SGLT2) inhibitors, when added to triple therapy including ACE-I/ARNI/beta-blocker/MRA, have been shown to minimize the risk of cardiovascular death and worsening HF in patients with HFrEF [11,12]. This evidence concerns the gene SLC5A2 and hydrops fetalis.